A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants
about
Determining biophysical protein stability in lysates by a fast proteolysis assay, FASTppComputational genes: a tool for molecular diagnosis and therapy of aberrant mutational phenotypePeptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of actionMolecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53.Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activityMutant p53: One, No One, and One Hundred ThousandTargeting Oncogenic Mutant p53 for Cancer TherapyProtein Folding and Mechanisms of ProteostasisChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingCrystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutationsTargeted rescue of a destabilized mutant of p53 by an in silico screened drugThe rebel angel: mutant p53 as the driving oncogene in breast cancer.To die or not to die: how does p53 decide?The ASPP interaction network: electrostatic differentiation between pro- and anti-apoptotic proteinsHighly homologous proteins exert opposite biological activities by using different interaction interfacesRegulation of ASPP2 interaction with p53 core domain by an intramolecular autoinhibitory mechanism.ASPP: a new family of oncogenes and tumour suppressor genes.High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones.Stability of the core domain of p53: insights from computer simulations.p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype.Targeting p53 for Novel Anticancer Therapy.Deciphering the folding transition state structure and denatured state properties of nucleophosmin C-terminal domain.SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor.Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation.The central region of HDM2 provides a second binding site for p53.αA-Crystallin-derived mini-chaperone modulates stability and function of cataract causing αAG98R-crystallinStabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domainNovel cancer therapy by reactivation of the p53 apoptosis pathway.Inhibiting HIV-1 integrase by shifting its oligomerization equilibriumThe tumor suppressor gene TP53: implications for cancer management and therapy.Apoptosis-based therapies and drug targets.Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.Mutant p53: one name, many proteins.Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.Exploiting the p53 pathway for the diagnosis and therapy of human cancer.Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
P2860
Q21030644-E0A8EDB3-65F8-4611-A1E1-6948F2242698Q21284221-4FB0F20C-D105-4F68-9E59-CCE336C75D33Q24316120-E8030473-0985-498A-B265-A4FDF5BD3519Q24336091-9CE7F980-00E8-4AE4-8842-BDDFDB48DC59Q24533476-A93DD933-4069-4CD8-A9D2-C8322B6E4EA9Q24628577-B919F7E0-FF8B-49B5-9BE0-01E827286878Q24800091-1748BA3F-7C2C-4506-8ECF-942D6993EE99Q26770576-026063E7-3C2A-4C36-8E40-F896B31DBED1Q26770856-1C29378E-4672-4C12-A865-3C526DB62915Q26801512-F7139B08-D703-4951-ACB2-3A84091ABFA7Q26863501-11EE4FDF-05EA-4C8D-95D9-F679C2AF33E0Q27642314-796ED730-A678-43D9-8B38-CA565F7F5E7DQ27651295-1E093736-6861-4067-8224-9711A2E173F3Q27686765-56EFB12C-8F9F-4256-AA84-B4A4BE40027AQ28255819-82AAC523-42B8-433B-B159-4157F7E5B71AQ28287668-858A1B05-AD2D-4AD3-84D2-C8FEAF317A52Q30009145-6EDD9121-A725-4B72-B0DD-FC55F06B24A8Q30009903-4E25DF9C-EB4C-4953-80AF-238C44B8A225Q31090644-C9536D3E-CA9B-46A9-BEA7-44DD7FAFA109Q33275131-2327AF2A-8F75-4640-970D-57E92B008220Q33322204-BA472629-F97B-4067-95EF-528E701B1D90Q33511752-BBD97828-CEA1-4F9E-877B-BEF8FE9D7463Q33655329-FDF26111-D2CB-49BC-9F27-78DFD583DE39Q33777703-56BB36E0-293C-4C6D-911C-DC8AEF40CE4AQ33795918-CAADF163-1485-4B58-862B-005F320C08DAQ33935212-C943FDE0-D14F-45D7-9B97-3D368D87DEE5Q34332782-59DD0DD4-11E8-4F7F-A01F-BE40B19227F5Q34335012-A8D0E81D-9096-4253-B0CA-00F7BEC57FFCQ34412182-7CE9A7F6-5626-4E49-B30D-76CED286B174Q34740058-88294486-4E2F-4BE5-AE16-AD28A31356EDQ35051686-C616B1D6-88D6-4912-A06D-5DE5234C4B61Q35597613-1944E076-337C-45FE-BD83-D276EC902769Q35850134-6B9DDABC-6B14-4B8A-A929-796D5BCDB328Q35986418-AE014A78-58C2-49A7-BCEE-E24E2BF80E21Q36017772-4882FDD7-DB15-42FE-9D60-955931E715DFQ36066191-35EEEFEA-B3FC-4E91-8C64-E9AED065EC22Q36070574-C85FA340-F04D-4A02-A539-71C172C2D287Q36187316-369E61DE-8BCE-451C-9703-71AFAC336825Q36547790-2B3AF539-5949-42C0-B591-966867729AFFQ36777373-7477B34C-18F6-45ED-B377-EA32D2AAC139
P2860
A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@ast
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@en
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@en-gb
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@nl
type
label
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@ast
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@en
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@en-gb
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@nl
prefLabel
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@ast
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@en
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@en-gb
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@nl
P2093
P2860
P50
P356
P1476
A peptide that binds and stabi ...... or rescue of oncogenic mutants
@en
P2093
Assaf Friedler
Mark R Proctor
Penka V Nikolova
Stefan M V Freund
Thomas M Rippin
P2860
P304
P356
10.1073/PNAS.241629998
P407
P577
2002-01-08T00:00:00Z